Search
Lilly's Oral GLP-1 Drug Approved in the U.S. for Weight Loss
1 week ago /
Read about 0 minute
Author：小编
On April 1 (local time), Eli Lilly and Company announced that its oral small-molecule GLP-1 receptor agonist, Orforglipron, has been approved by the U.S. FDA for marketing, intended for the treatment of obesity or overweight in adults. The product will be sold under the brand name Foundayo, with shipments starting from April 6.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
